Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects
Authors
Keywords
-
Journal
BRAIN
Volume 138, Issue 9, Pages 2701-2715
Publisher
Oxford University Press (OUP)
Online
2015-07-29
DOI
10.1093/brain/awv199
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years
- (2017) Joakim Hertze et al. JOURNAL OF ALZHEIMERS DISEASE
- PART, a distinct tauopathy, different from classical sporadic Alzheimer disease
- (2015) Kurt A. Jellinger et al. ACTA NEUROPATHOLOGICA
- Age, Sex, andAPOEε4 Effects on Memory, Brain Structure, and β-Amyloid Across the Adult Life Span
- (2015) Clifford R. Jack et al. JAMA Neurology
- Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease
- (2015) Jon B. Toledo et al. JAMA Neurology
- Primary age-related tauopathy (PART): a common pathology associated with human aging
- (2014) John F. Crary et al. ACTA NEUROPATHOLOGICA
- Alzheimer Disease Cerebrospinal Fluid Biomarkers Predict Cognitive Decline In Healthy Elderly Over 2 Years
- (2014) Ruth Gasparini Berenguer et al. ALZHEIMER DISEASE & ASSOCIATED DISORDERS
- Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease
- (2014) Niklas Mattsson et al. BRAIN
- Challenges of multimorbidity of the aging brain: a critical update
- (2014) Kurt A. Jellinger et al. JOURNAL OF NEURAL TRANSMISSION
- Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50–89 years: a cross-sectional study
- (2014) Clifford R Jack et al. LANCET NEUROLOGY
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease
- (2014) A. M. Fagan et al. Science Translational Medicine
- Prevalence of mixed pathologies in the aging brain
- (2014) Jasmin Rahimi et al. Alzheimers Research & Therapy
- Cross-Sectional and Longitudinal Relationships Between Cerebrospinal Fluid Biomarkers and Cognitive Function in People Without Cognitive Impairment From Across the Adult Life Span
- (2014) Ge Li et al. JAMA Neurology
- Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42
- (2014) Sebastian Palmqvist et al. JAMA Neurology
- Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease
- (2014) Ronald Lautner et al. JAMA Psychiatry
- Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
- (2014) Jon B Toledo et al. Acta Neuropathologica Communications
- Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
- (2013) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series
- (2013) Gabor G. Kovacs et al. ACTA NEUROPATHOLOGICA
- The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
- (2013) Michael W. Weiner et al. Alzheimers & Dementia
- A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank
- (2013) Jon B. Toledo et al. Alzheimers & Dementia
- Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid
- (2013) Susan M. Landau et al. ANNALS OF NEUROLOGY
- Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer’s Coordinating Centre
- (2013) Jon B. Toledo et al. BRAIN
- Clinical Utility and Analytical Challenges in Measurement of Cerebrospinal Fluid Amyloid- 1-42 and Proteins as Alzheimer Disease Biomarkers
- (2013) J.-H. Kang et al. CLINICAL CHEMISTRY
- Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
- (2013) Clifford R Jack et al. LANCET NEUROLOGY
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease
- (2013) Stefan Teipel et al. NEUROBIOLOGY OF AGING
- A 2-process model for neuropathology of Alzheimer's disease
- (2013) Dan Mungas et al. NEUROBIOLOGY OF AGING
- CSF biomarker changes precede symptom onset of mild cognitive impairment
- (2013) A. Moghekar et al. NEUROLOGY
- Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity
- (2013) C. R. Jack et al. NEUROLOGY
- Brain -amyloid load approaches a plateau
- (2013) C. R. Jack et al. NEUROLOGY
- Clinical and multimodal biomarker correlates of ADNI neuropathological findings
- (2013) Jon B Toledo et al. Acta Neuropathologica Communications
- CSF biomarkers cutoffs: the importance of coincident neuropathological diseases
- (2012) Jon B. Toledo et al. ACTA NEUROPATHOLOGICA
- Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults
- (2012) Donata Paternicò et al. Alzheimers & Dementia
- National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease
- (2012) Bradley T. Hyman et al. Alzheimers & Dementia
- Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints
- (2012) Argonde C. van Harten et al. Alzheimers & Dementia
- Comparison of Cerebrospinal Fluid Levels of Tau and Aβ 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms
- (2012) David J. Irwin et al. ARCHIVES OF NEUROLOGY
- Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
- (2012) Eric M Reiman et al. LANCET NEUROLOGY
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach
- (2011) Thomas J. Montine et al. ACTA NEUROPATHOLOGICA
- An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease
- (2011) Clifford R. Jack et al. ANNALS OF NEUROLOGY
- Comparison of Analytical Platforms for Cerebrospinal Fluid Measures of β-Amyloid 1-42, Total tau, and P-tau181 for Identifying Alzheimer Disease Amyloid Plaque Pathology
- (2011) Anne M. Fagan ARCHIVES OF NEUROLOGY
- The pathological process underlying Alzheimer’s disease in individuals under thirty
- (2010) Heiko Braak et al. ACTA NEUROPATHOLOGICA
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People
- (2010) Geert De Meyer ARCHIVES OF NEUROLOGY
- The Cerebrospinal Fluid Amyloid β42/40 Ratio in the Differentiation of Alzheimers Disease from Non-Alzheimers Dementia
- (2010) P.E. Spies et al. Current Alzheimer Research
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
- (2009) Leslie M. Shaw et al. ANNALS OF NEUROLOGY
- Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
- (2009) Tero Tapiola et al. ARCHIVES OF NEUROLOGY
- Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
- (2008) Howard Jay Aizenstein et al. ARCHIVES OF NEUROLOGY
- The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease
- (2007) Lidia Glodzik-Sobanska et al. NEUROBIOLOGY OF AGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started